{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:50:20Z","timestamp":1785358220779,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer Center Support Grant","award":["P30CA 86862"],"award-info":[{"award-number":["P30CA 86862"]}]},{"name":"Maxene Spohnheimer Thyroid Cancer Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Molecular profiling has refined the identification of pathologic subtypes in other cancers, but is not currently used for prognostication in papillary thyroid cancer (PTC). The cancer stem cell marker, CD133, is a glycoprotein associated with tumor initiation and radioresistance in PTC, but its role in prognostication continues to be defined. This study sought to define the association between CD133 expression in PTC and recurrence-free survival (RFS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All the patients at a single institution with PTC who underwent thyroidectomy from 2008 to 2011 were identified through an electronic medical record query. Immunohistochemistry was performed for CD133, and the H-score was calculated. Receive operating characteristic (ROC) curves were used to identify the optimal cutoff for CD133 expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 110 consecutive patients were identified, and 12% had a biopsy-proven recurrence during a median follow-up period of 10.1 years (interquartile range [IQR], 8.3\u201311.5 years). The median H-score did not differ significantly between the patients who experienced recurrence (74; IQR, 59\u201381) and those who did not (70; IQR, 51\u201389). An H-score of 55 or higher identified patients who had a recurrence with 92% sensitivity. Among the patients with a CD133 H-score of 55 or higher, males had a significantly worse RFS than females (<jats:italic>p<\/jats:italic> = 0.005), but RFS did not differ between males and females with a CD133 H-score lower than 55 (<jats:italic>p<\/jats:italic> = 0.739).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A clear role of CD133 in prognostication has not been defined to date. Expression of CD133 and its association with survival varies between males and females, with stratification of recurrence risk more prominent in males.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17256-2","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:35:33Z","timestamp":1744371333000},"page":"4772-4779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of Recurrence and Cancer Stem Cell Marker CD133 Expression Vary in Males Versus Females with Papillary Thyroid Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Jeremy","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyas M.","family":"Alzayadneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-9540","authenticated-orcid":false,"given":"Anna C.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"17256_CR1","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1245\/s10434-008-9859-4","volume":"15","author":"A Toniato","year":"2008","unstructured":"Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15:1518\u201322. https:\/\/doi.org\/10.1245\/s10434-008-9859-4.","journal-title":"Ann Surg Oncol"},{"key":"17256_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/RLU.0b013e31805375ca","volume":"32","author":"MR Pelizzo","year":"2007","unstructured":"Pelizzo MR, Boschin IM, Toniato A, et al. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med. 2007;32:440\u20134. https:\/\/doi.org\/10.1097\/RLU.0b013e31805375ca.","journal-title":"Clin Nucl Med"},{"key":"17256_CR3","unstructured":"Thyroid Cancer Survival Rates, by Type and Stage. https:\/\/www.cancer.org\/cancer\/types\/thyroid-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed 12 Sept 2024."},{"key":"17256_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"key":"17256_CR5","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1210\/jc.2011-1469","volume":"96","author":"YE Nikiforov","year":"2011","unstructured":"Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390\u20137. https:\/\/doi.org\/10.1210\/jc.2011-1469.","journal-title":"J Clin Endocrinol Metab"},{"key":"17256_CR6","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1210\/jc.2009-0247","volume":"94","author":"YE Nikiforov","year":"2009","unstructured":"Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092\u20138. https:\/\/doi.org\/10.1210\/jc.2009-0247.","journal-title":"J Clin Endocrinol Metab"},{"key":"17256_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1203208","volume":"367","author":"EK Alexander","year":"2012","unstructured":"Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1203208.","journal-title":"N Engl J Med"},{"key":"17256_CR8","first-page":"1050","volume":"114","author":"ID Hay","year":"1993","unstructured":"Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050\u20137; discussion 1057-8.","journal-title":"Surgery"},{"key":"17256_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid. 2010;20:1341\u20139. https:\/\/doi.org\/10.1089\/thy.2010.0178.","journal-title":"Thyroid"},{"key":"17256_CR10","doi-asserted-by":"publisher","first-page":"114801","DOI":"10.18632\/oncotarget.21954","volume":"8","author":"JP De Andrade","year":"2017","unstructured":"De Andrade JP, Lorenzen AW, Wu VT, et al. Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer. Oncotarget. 2017;8:114801\u201315. https:\/\/doi.org\/10.18632\/oncotarget.21954.","journal-title":"Oncotarget"},{"key":"17256_CR11","first-page":"755","volume":"3","author":"J Liu","year":"2010","unstructured":"Liu J, Brown RE. Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp Pathol. 2010;3:755\u201362.","journal-title":"Int J Clin Exp Pathol"},{"key":"17256_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1210\/jc.2013-2558","volume":"99","author":"SH Ahn","year":"2014","unstructured":"Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99:536\u201344. https:\/\/doi.org\/10.1210\/jc.2013-2558.","journal-title":"J Clin Endocrinol Metab"},{"key":"17256_CR13","doi-asserted-by":"publisher","first-page":"e5395","DOI":"10.1371\/journal.pone.0005395","volume":"4","author":"S Friedman","year":"2009","unstructured":"Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS ONE. 2009;4:e5395. https:\/\/doi.org\/10.1371\/journal.pone.0005395.","journal-title":"PLoS ONE"},{"key":"17256_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4614-5894-4_1","volume":"777","author":"D Corbeil","year":"2013","unstructured":"Corbeil D, Karbanova J, Fargeas CA, Jaszai J. Prominin-1 (CD133): molecular and cellular features across species. Adv Exp Med Biol. 2013;777:3\u201324. https:\/\/doi.org\/10.1007\/978-1-4614-5894-4_1.","journal-title":"Adv Exp Med Biol"},{"key":"17256_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","volume":"7","author":"PM Glumac","year":"2018","unstructured":"Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7:18. https:\/\/doi.org\/10.1186\/s40169-018-0198-1.","journal-title":"Clin Transl Med"},{"key":"17256_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-012-2242-5","volume":"40","author":"CC Ke","year":"2013","unstructured":"Ke CC, Liu RS, Yang AH, et al. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 2013;40:61\u201371. https:\/\/doi.org\/10.1007\/s00259-012-2242-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17256_CR17","doi-asserted-by":"publisher","first-page":"e0182835","DOI":"10.1371\/journal.pone.0182835","volume":"12","author":"D Mei","year":"2017","unstructured":"Mei D, Lv B, Chen B, et al. All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis. PLoS ONE. 2017;12:e0182835. https:\/\/doi.org\/10.1371\/journal.pone.0182835.","journal-title":"PLoS ONE"},{"key":"17256_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2019.02.023","volume":"511","author":"C Wang","year":"2019","unstructured":"Wang C, Wang Z, Liu W, Ai Z. CD133 promotes the self-renewal capacity of thyroid cancer stem cells through activation of glutamate aspartate transporter SLC1A3 expression. Biochem Biophys Res Commun. 2019;511:87\u201391. https:\/\/doi.org\/10.1016\/j.bbrc.2019.02.023.","journal-title":"Biochem Biophys Res Commun"},{"key":"17256_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fendo.2019.00523","volume":"10","author":"HM Kim","year":"2019","unstructured":"Kim HM, Koo JS. Immunohistochemical analysis of cancer stem cell marker expression in papillary thyroid cancer. Front Endocrinol Lausanne. 2019;10:523. https:\/\/doi.org\/10.3389\/fendo.2019.00523.","journal-title":"Front Endocrinol Lausanne"},{"key":"17256_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3892\/mco.2022.2574","volume":"17","author":"D Li","year":"2022","unstructured":"Li D, Li N, Ding Y. Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients. Mol Clin Oncol. 2022;17:141. https:\/\/doi.org\/10.3892\/mco.2022.2574.","journal-title":"Mol Clin Oncol"},{"key":"17256_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.prp.2017.05.002","volume":"213","author":"SA Han","year":"2017","unstructured":"Han SA, Jang JH, Won KY, Lim SJ, Song JY. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma. Pathol Res Pract. 2017;213:956\u201363. https:\/\/doi.org\/10.1016\/j.prp.2017.05.002.","journal-title":"Pathol Res Pract"},{"key":"17256_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1177\/107327481502200418","volume":"22","author":"Z Lin","year":"2015","unstructured":"Lin Z, Lu X, Li W, et al. Association of cancer stem cell markers with aggressive tumor features in papillary thyroid carcinoma. Cancer Control. 2015;22:508\u201314. https:\/\/doi.org\/10.1177\/107327481502200418.","journal-title":"Cancer Control"},{"key":"17256_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.5114\/aoms\/185169","volume":"20","author":"X Peng","year":"2024","unstructured":"Peng X, Zhu P, Zhang Q, Li J. The prognostic value of cancer stem cell markers in thyroid cancer: a systematic review. Arch Med Sci. 2024;20:686\u201390. https:\/\/doi.org\/10.5114\/aoms\/185169.","journal-title":"Arch Med Sci"},{"key":"17256_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.surg.2021.03.076","volume":"171","author":"AC Beck","year":"2022","unstructured":"Beck AC, Rajan A, Landers S, et al. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer. Surgery. 2022;171:245\u201351. https:\/\/doi.org\/10.1016\/j.surg.2021.03.076.","journal-title":"Surgery"},{"issue":"11","key":"17256_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1089\/thy.2024.0271","volume":"34","author":"DJ van de Berg","year":"2024","unstructured":"van de Berg DJ, et al. The definition of recurrence of differentiated thyroid cancer: a systematic review of the literature. Thyroid. 2024;34(11):1324\u201334.","journal-title":"Thyroid"},{"key":"17256_CR26","unstructured":"DensitoQuant Module in QuantCenter. https:\/\/www.3dhistech.com\/quantmodules\/densitoquant\/. Accessed 29 Jan 2024."},{"key":"17256_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/jamainternmed.2021.4804","volume":"181","author":"K LeClair","year":"2021","unstructured":"LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Intern Med. 2021;181:1351\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2021.4804.","journal-title":"JAMA Intern Med"},{"key":"17256_CR28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/coa.14075","volume":"48","author":"GB Morand","year":"2023","unstructured":"Morand GB, Tessler I, Krasner J, et al. Investigation of genetic sex-specific molecular profile in well-differentiated thyroid cancer: is there a difference between females and males? Clin Otolaryngol. 2023;48:748\u201355. https:\/\/doi.org\/10.1111\/coa.14075.","journal-title":"Clin Otolaryngol"},{"key":"17256_CR29","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2018.78.5097","volume":"36","author":"F Wang","year":"2018","unstructured":"Wang F, Zhao S, Shen X, et al. BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer. J Clin Oncol. 2018;36:2787\u201395. https:\/\/doi.org\/10.1200\/JCO.2018.78.5097.","journal-title":"J Clin Oncol"},{"key":"17256_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/JOE-13-0029","volume":"218","author":"S Xu","year":"2013","unstructured":"Xu S, Chen G, Peng W, Renko K, Derwahl M. Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules. J Endocrinol. 2013;218:125\u201333.","journal-title":"J Endocrinol"},{"key":"17256_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopha.2016.11.043","volume":"85","author":"M Zane","year":"2017","unstructured":"Zane M, Parello C, Pennelli G, Townsend DM, Merigliano S, Boscaro M, et al. Estrogen and thyroid cancer is a stem affair: a preliminary study. Biomed Pharmacother. 2017;85:399\u2013411.","journal-title":"Biomed Pharmacother"},{"key":"17256_CR32","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1210\/clinem\/dgaa527","volume":"105","author":"A Cordero Barreal","year":"2020","unstructured":"Cordero Barreal A, Caleiras E, Lopez de Maturana E, et al. CD133 expression in medullary thyroid cancer cells identifies patients with poor prognosis. J Clin Endocrinol Metab. 2020;105:3548. https:\/\/doi.org\/10.1210\/clinem\/dgaa527.","journal-title":"J Clin Endocrinol Metab"},{"key":"17256_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jso.24124","volume":"113","author":"Y Bi","year":"2016","unstructured":"Bi Y, Meng Y, Wu H, Cui Q, Luo Y, Xue X. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: a ten-year follow-up and prognostic analysis. J Surg Oncol. 2016;113:144\u201351. https:\/\/doi.org\/10.1002\/jso.24124.","journal-title":"J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17256-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:57:42Z","timestamp":1748869062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17256-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["17256"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17256-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}